Japan's Chugai, Bioventure to Co-Develop Antibody Drugs (Japan)
This article was originally published in PharmAsia News
Chugai Pharmaceutical Co. has signed an agreement for the collaborative development of antibody drugs with bioventure Chiome Bioscience Inc., which has a proprietary technology using chicken immunocytes grown in cultures to create antibodies in just a week, compared with the months it ordinarily takes using lab animals. Chugai has already commercialized one antibody drug, and wants to use Chiome's technologies to develop antibodies against a variety of disease marker proteins. The antibodies will form the material basis enabling Chugai to develop other antibody drugs, with a focus on diagnostics and therapeutics for cancers and immune disorders. (Print Edition Only: Link to Full Text Unavailable
You may also be interested in...
Royal Philips will make 43,000 medical ventilators by year-end for use in the US and make 2,500 more for the Strategic National Stockpile in a deal with the US government worth $646.7m. See what Philips’ CEO Frans van Houten said about it here.
Pharma manufacturing is operating well below normal levels in India, disrupted by labor absenteeism and supply chain issues amid the ongoing lock-down in the country, though the government is actively engaged in addressing bottlenecks. A speedy recovery is vital not just for domestic supplies.
Moderna is pursuing a single-antigen strategy even though some of its mRNA vaccines have included multiple antigens; the SARS-CoV-2 spike protein likely provides the best antigen for developing immunity against the virus.